DENALI THERAPEUTICS INC's ticker is DNLI and the CUSIP is 24823R105. A total of 186 filers reported holding DENALI THERAPEUTICS INC in Q2 2022. The put-call ratio across all filers is 0.37 and the average weighting 0.3%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q2 2023 | $240,949 | +13.7% | 8,165 | -11.3% | 0.00% | – |
Q1 2023 | $211,991 | -71.0% | 9,201 | -59.4% | 0.00% | -100.0% |
Q1 2022 | $730,000 | -68.3% | 22,686 | -56.1% | 0.00% | -75.0% |
Q4 2021 | $2,304,000 | -44.3% | 51,667 | -37.0% | 0.00% | -50.0% |
Q3 2021 | $4,139,000 | -33.4% | 82,049 | +3.5% | 0.01% | -27.3% |
Q2 2021 | $6,219,000 | +25.7% | 79,284 | -8.5% | 0.01% | +37.5% |
Q1 2021 | $4,946,000 | -7.5% | 86,624 | +35.6% | 0.01% | -11.1% |
Q4 2020 | $5,349,000 | +191.3% | 63,867 | +24.6% | 0.01% | +200.0% |
Q3 2020 | $1,836,000 | +163.0% | 51,247 | +77.5% | 0.00% | +200.0% |
Q2 2020 | $698,000 | +48.5% | 28,877 | +7.6% | 0.00% | 0.0% |
Q1 2020 | $470,000 | -45.2% | 26,830 | -45.5% | 0.00% | 0.0% |
Q4 2019 | $857,000 | -18.9% | 49,205 | -28.7% | 0.00% | 0.0% |
Q3 2019 | $1,057,000 | +391.6% | 68,994 | +566.9% | 0.00% | – |
Q2 2019 | $215,000 | – | 10,346 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Crestline Management, LP | 19,462,500 | $339,037,000 | 35.95% |
Euclidean Capital LLC | 323,749 | $27,117,000 | 5.74% |
Flagship Pioneering Inc. | 2,730,263 | $228,687,000 | 4.16% |
Casdin Capital, LLC | 1,310,000 | $109,726,000 | 3.25% |
A.R.T. Advisors, LLC | 6,173 | $517,000 | 2.39% |
MARK ASSET MANAGEMENT LP | 172,040 | $14,410,000 | 1.73% |
Temasek Holdings (Private) Ltd | 4,410,457 | $369,420,000 | 1.59% |
Integral Health Asset Management, LLC | 57,500 | $4,816,000 | 1.43% |
GILDER GAGNON HOWE & CO LLC | 3,219,843 | $269,694,000 | 1.34% |
IRONWOOD INVESTMENT MANAGEMENT LLC | 19,365 | $1,622,000 | 0.95% |